• GRCK develops high technology, cloud-based software designed to detect online fraud
• Company owns proprietary FraudLytic™ digital platform that monitors internet traffic in real time
• CFO said uplisting will raise visibility of GRCK to investment community, grow company

Grey Cloak Tech, Inc. (OTCQB: GRCK) has been uplisted to the OTCQB Venture Market (http://dtn.fm/3IIb3), but its ticker symbol remains unchanged at GRCK, the company announced. William Bossung, CFO, said that the uplisting would help raise the exposure of the company to the investment community. The change is effective immediately.

GRCK is a Las Vegas, Nevada-based company that develops high technology software designed to overcome the impact of costly digital threats. It is also designed to eliminate online fraud. It manufactures FraudLytic™, a cloud-based proprietary digital platform that monitors internet traffic in real time. This platform is specifically designed to prevent digital advertisers from online sites wrongly claiming the number of clicks to internet advertisers.

“Trading on the OTCQB will raise visibility of Grey Cloak Tech in the investment community,” Bossung said. “It’s an important step towards building Grey Cloak Tech into a larger company. We are pleased with this key improvement in the market positioning of our organization.”

OTCQB is a venture market designed for early stage and developing U.S. and international companies, GRCK said. To be eligible to join, firms must be current in their financial reporting and annually submit to a verification and to a management certification process.

For more information, visit the company’s website at www.GreyCloakTech.com

• U.S. ranks last in health care access, spending twice as much as other high-income countries
• 80+ million Americans live in rural areas where health care access is limited
• MIHI building nationwide telemedicine network to serve underserved Americans

America ranks dead last among 11 developed high-income countries for overall health care performance and nearly last when it comes to health care access, administrative efficiency, and health care outcomes, according to a new report published by the Commonwealth Fund (http://dtn.fm/6dZH7). In excess of $9,000 per capita, the United States spends far more on health care than any country in the world and virtually double what each of the other comparative countries in the report spend, but the U.S. falls abysmally short of the performance achieved by the other high-income countries. The United States of America ranks at the very bottom in health care access and health care outcomes and ranks very poorly in infant mortality and life expectancy at age 60. The really sad part is that the United States has firmly held this expensive last place health care position for at least a decade.

Dramatically impacting health care access, an estimated 80 million Americans live in rural areas where access to medical services is extremely limited. These regions suffer from a chronic shortage of not only primary care physicians but, even more critically, specialty care physicians. Targeting these medically underserved areas, Medical Innovation Holdings, Inc. (OTC: MIHI) intends to deliver much needed medical care while simultaneously developing the foundation of its unique business model.

Utilizing telemedicine to connect specialty physicians to diverse rural areas, MIHI is committed to expanding and disrupting the traditional telemedicine business model, building a national network of physicians and patients, and vertically integrating multiple health care-related products and services across multiple platforms throughout its entire network. The company’s business model provides much needed specialty practice medical services to underserved rural patients in the setting of their primary practice provider. It also provides the rural physician with administrative support, additional income through more product and service offerings, and the ability for the rural practice to grow exponentially while providing access to specialist practitioners.

The telehealth market is projected to grow at a CAGR of 27.5% over the next five years, from 2016 to 2021 (http://dtn.fm/VriD9). The growth of the overall market can be attributed to growth in the geriatric population, dearth of health care professionals worldwide, improvements in telecommunication infrastructure, technological advancements, increasing utilization of connected devices for the management of chronic diseases, and a need for affordable treatment options due to rising health care costs. Medical Innovation Holdings fully intends to fulfill many of these health care needs while capitalizing on the phenomenal compound annual growth.

The recent editorial “Telemedicine: Reducing the Costs” (http://dtn.fm/05oZN) outlines MIHI’s vastly different approach from a growing field of telemedicine providers by delivering virtual telemedicine with a unique, customized software and hardware platform. Given its mutually beneficial business model and the dire need for health care access in the U.S., Medical Innovation Holdings could greatly contribute to getting the country out of last place in health care and back to healing America.

For more information, visit the company’s website at www.MedicalInnovationHoldings.com

Let us hear your thoughts: Medical Innovation Holdings, Inc. Message Board

• New strategy in China is targeted to gain share in online-to-offline (O2O) market, grow processing fees, and boost revenues from converting its platforms to paid
• Crystal Equity Research has set a $5.25 price on MOXC stock and projects sales of $2.3 million by FY2018 with gross profit of $1.7 million
• China Daily reports retail sales in China grew 10.4% YOY to $2.55 trillion in 1H2017

Moxian, Inc. (NASDAQ: MOXC) is now focusing on larger retailers ($2-$4 million in annual sales) to grow its Moxian+ Merchant App in the Online-To-Offline (O2O) market, setting its sights on more business subscribers, increased commission revenues on sales processed by its UnionPay mobile module, and selling subscriber merchants sophisticated data on consumers.

The new strategy is part of MOXC’s shift towards gaining more market share in China with its paid platforms Moxian+ Merchant App and Moxian+ User App, for consumers. Smaller retailers are attracted to larger volume networks, such as Alibaba’s Taobao platform. Instead, MOXC sees the benefit of faster growth by targeting larger retailers in China.

MOXC is a Shenzhen, China-based development-stage company working to convert its formerly-free platforms into paid apps that generate revenues from subscriptions, advertising, marketing, and fees earned from payments processed by its UnionPay module.

Crystal Equity Research has set a $5.25 price on MOXC stock and projects its sales will reach $2.3 million by FY2018 with a gross profit of $1.7 million (http://dtn.fm/tR8Vq). China Daily reports that first half 2017 retail sales grew 10.4% YOY to $2.55 trillion in 1H2017 (http://dtn.fm/e5gIL).

MOXC’s strategy shift is also repositioning its sales managers to work with independent agents by market. Within four years, the company anticipates building networks with 500-1,000 agents in each market. The goal is lower SG&A expenses and better align expenses to revenue streams from new customers, the report said.

Previously, MOXC’s strategy was to pursue smaller retailers. But a lot of O2O competition for that business is a factor — making it inefficient and costly for MOXC to grow market share. By targeting larger retailers, MOXC now sees opportunity to process more sales and earn more revenue as a percentage of those sales. The company can also charge larger retailers fees by offering additional data that targets the Chinese digital consumer market.

For more information, visit the company’s website at www.Moxian.com

• Increases choices by allowing electronic payment for lottery tickets
• Improves consumer experience: play online from home
• Expansive market: half of adult Americans play the lottery

If you’re tired of standing in line to play Powerball, Mega Millions or SuperLotto Plus, then you should consider signing up for an account with LottoGopher Holdings Inc. (OTCQB: LTTGF) (CSE: LOTO) (FRA: 2LG). A paid subscription account with the lottery messenger service allows users the convenience of ordering tickets from the safety and comfort of their homes or offices. No more standing in line on rainy days; no more tussling with unruly fellow customers; a LottoGopher account lets you purchase a lottery ticket without hassle…and at the same price you always pay. As the U.S. economy moves increasingly away from cash, LottoGopher is poised to make its business model part of that cashless world. This Los Angeles, California-based innovator is giving the U.S. lotteries business a ticket to win big as adoption of its technology grows.

Despite the widespread adoption of electronic payments, the typical lotto player generally needs to pay for his ticket with cash if he lives in the District of Columbia, Puerto Rico, the U.S. Virgin Islands or any of the 44 states that are members of the Multi-State Lottery Association (MUSL). Six (6) states (Alabama, Alaska, Hawaii, Mississippi, Nevada, and Utah) have no lotteries. A number of jurisdictions, such as Arkansas, New Mexico, South Carolina, Tennessee, Washington, DC and Wisconsin, only permit cash sales of lotto tickets. In some other states (Connecticut, Iowa, Kansas, Louisiana, Minnesota, Nebraska, New York, North Dakota, Pennsylvania, South Dakota, Washington), although debit cards are allowed by state law, it’s up to the retailer whether to take them or not.

Paying for a lotto ticket with a credit card, although generally frowned upon, is allowed by at least twenty (20) of the forty-seven (47) jurisdictions that are part of the MUSL: Arizona, California, Delaware, Idaho, Illinois, Indiana, Kansas, Louisiana, Maine, Michigan, Minnesota, Nebraska, New York, Ohio, Oregon, Pennsylvania, Rhode Island, South Dakota, Vermont, and Washington. In California, credit card payments are only accepted at designated gas pumps with lottery ticket sale options. In the world of sweepstakes, cash remains king.

And its dominion is extensive; in the U.S., $80 billion is spent on lotteries every year. With about half of adult Americans (approximately 120 million) playing the lottery on a regular basis, according to Gallup (http://dtn.fm/4ngZu), LottoGopher’s target market is just as expansive. At present, the company’s service is only available in California, where residents spent about $6.3 billion on various lotteries, but LottoGopher plans to offer its daily, monthly and annual subscriptions to customers in at least twenty-two (22) other states over the next few years. LottoGopher’s lottery messenger service provides its subscribers with the security of ordering and managing the legal purchase of state lottery tickets online using debit and credit cards. The service allows users to keep track of tickets and winnings and gives them exclusive access to strategies, alerts, and lottery news. Account holders can play alone with a single ticket or join online public or private groups to pool winnings. LottoGopher’s support systems include an automated email follow-up system to capture, score and remarket to email address leads, a social media listening and outreach feature and utilization of Google Analytics tools.

To scale up operations rapidly, LottoGopher has joined forces with Lottoland, the world leader in online lottery. Since launching in 2013, Lottoland has climbed to €300 million in annual sales and now has six (6) million customers on its books. It’s a partnership that is quite likely to hit the jackpot.

For more information, visit the company’s website at www.LottoGopher.com

Let us hear your thoughts: LottoGopher Holdings Inc. Message Board

• CIIX reported nearly 76 percent revenue growth for full year fiscal 2017
• Price target of $3.75 reflects investment potential of cannabis initiatives
• Recent launch of cryptocurrency daily Chinese video newscast from NYSE first of its kind
• CBD industry is expected to grow to $2.1 million in consumer sales by 2020 with $450 million coming from hemp-based sources.

ChineseInvestors.com, Inc. (OTCQB: CIIX), a leading financial information website for Chinese-speaking investors in the United States, China and Canada, continues to innovate and create exceptional value opportunities with the launch of a CBD skincare line in China and a cryptocurrency daily Chinese video newscast from the NYSE. Notably, SeeThruEquity has updated and maintained its target price of $3.75 on shares of ChineseInvestors.com, Inc.’s stock.

Among the reported highlights is the company’s revenue growth of 75.9% over 2016, with revenues dramatically increasing in both its investor relations and subscription services segments (http://dtn.fm/j6BZV). CIIX’s business strategy of targeting the emerging cannabidiol (CBD) health products market includes bringing a new website online for its subsidiary ChineseCBDoil.com (http://dtn.fm/y7S5i). This website offers the world’s first “CBD health products online store in the Chinese language.” At the same time, CIIX launched a Chinese language Yelp-style mobile application that contains a location-enabled database of recreational and medical marijuana dispensaries, as well as a platform to review and discuss various cannabis and CBD products.

The company’s wholly owned foreign subsidiary CBD Biotechnology recently completed the record filing process with the China Food & Drug Administration for its first retail line of hemp-infused skin care products. With this essential regulatory milestone met and several products designed and manufactured, ChineseInvestors.com is ready to promote and sell its CBD Hemp Oil and CBD infused skin care products in China, Alan Klitenic, CIIX director of investor relations said in a SmallCapVoice interview (http://dtn.fm/IdN8E).

Adding to the company’s robust growth pattern, the launch this week of the first cryptocurrency daily video newscast in the Chinese language from the NYSE is generating attention. Titled “Bitcoin Multimillionaire,” the video newscast aims to provide information and analysis regarding all aspects of the emerging digital currency world.

“Many Chinese investors are seeking information and education related to the cryptocurrency sector,” said Warren Wang, founder and CEO of CIIX said in a news release (http://dtn.fm/Fw59W). “Similar to U.S. stocks, as the price of digital currency, such as Bitcoin, continues to increase, Chinese people all over the world are taking notice and seeking access to timely information regarding market trends, news and analysis. We look forward to being the premier source for this information.”

Investors should also watch for CIXX to launch a website to serve the Chinese cryptocurrency investor. The new site, located at newcoin168.com, will seek to “be a leader in digital media and cryptocurrency and blockchain technology education,” providing straight forward explanations on all aspects of the cryptocurrency market while providing strategies and other opportunities to capitalize on this fast-paced financial industry.

For more information, visit the company’s website at www.ChineseInvestors.com

Let us hear your thoughts: ChineseInvestors.com, Inc. Message Board

• Demand for alternative fuel vehicles & systems climbing
• CNG and LPG have smaller carbon footprints
• Natural gases cost less than gasoline or diesel

As a major player in the clean energy truck market, Greenkraft, Inc. (OTCQB: GKIT) is offering truck fleet operators the rare opportunity to have their cake and eat it too. The California-based manufacturer not only provides alternative fuel automotive products that are more environmentally friendly but they are, also, more cost effective. Utilizing an engine, or commercial truck or alternative fuel system from Greenkraft, fleet owners can play a part in preserving the planet, while boosting their bottom lines. They are already starting to do so. The company has reported increased demand for its trucks and is ramping up its production facilities to turn out more fuel-efficient trucks with varying carrying capacities.

Despite the naysayers, the Paris Climate Accord, signed by 195 nation-states, was recognition that carbon emissions are causing global warming and climate change. The Accord aims to ‘keep the increase in global average temperature to well below 2°C above pre-industrial levels’ and an obvious way to do that is by a reducing or eliminating the use of fossil fuels. However, with regard to the greenhouse gases (GHG) that result when they are burned, fossil fuels are not all the same. Naturally occurring gases, which are components of liquefied petroleum gas (LPG) and compressed natural gas (CNG) have much smaller carbon footprints than either gasoline or diesel.

CNG is mainly methane obtained from natural gas, oil wells and coal beds that has been compressed to a pressure around 200 times normal atmospheric pressure. LPG is mostly propane and butane from gas fields or from oil refining at a pressure of between 5-15 atmospheric pressures. Using the Greenhouse gases, Regulated Emissions, and Energy use in Transportation Model (GREET) framework, the Argonne National Laboratory’s Systems Assessment Group has reported ‘that propane use reduced GHG emissions by nearly 10%’ (http://dtn.fm/3cMlW). And the California Air Resources Board (CARB) has found that a CNG fueled vehicle emits 20 to 29 percent fewer GHG emissions than a comparable gasoline or diesel fueled vehicle.

Natural gases are also less expensive. A study by SoCalGas concluded that vehicles powered by CNG offer substantial advantages over vehicles powered by gasoline or diesel (http://dtn.fm/5jY8v). Researchers compared heavy-duty commercial diesel and natural gas vehicles and provided estimated break-even points, i.e. the prices at which it would be equally cost effective to use either natural gases or diesel. For a transit bus, the oil price would have to fall to $31 per barrel; for a short- haul heavy-duty truck, it would need to drop to $28 a barrel, while for a refuse hauler, the oil price would have to sink to $22 a barrel.

With the global alternative fuel market set to grow to $614 billion by 2022, Greenkraft is planning to expand its output by the construction of a larger manufacturing facility. In March, the company announced the debut of the Greenkraft truck at the WWETT Show 2017 held on February 22 – February 25 at the Indiana Convention Center. The truck’s coming out generated a lot of excitement, particularly since it allowed the Greenkraft brand to be introduced to the septic tank sector of the trucking industry.

George Gemayel, CEO of Greenkraft, Inc. had this to say, “The debut of our trucks at the WWETT Show was a huge success as everyone was amazed at how the Greenkraft truck looked. In addition, this opens up an entire new market for Greenkraft since we had not previously focused on the septic tank industry; but now it can produce millions of new revenue dollars for the Company in the coming years.”

For more information, visit the company’s website at www.GreenkraftInc.com

Let us hear your thoughts: Greenkraft, Inc. Message Board

• Web-meeting scheduled for November 1, 2017, at 4:15 p.m. ET
• 19 patents filed encompassing 44 countries
• Patents cover broad range of lipophilic bio-actives including cannabinoids, vitamins and other pharma
• Patented lipophilic delivery system proven to improve bio-absorption

The medical effectiveness of cannabinoids is no longer in question, and the cannabinoid market proliferates ever faster as more people realize the therapeutic benefits. However, the human gastrointestinal tract just doesn’t absorb cannabinoids effectively, and much of what is ingested is subsequently excreted by the body, causing onset times and efficacy to vary wildly.

With 19 patent applications filed internationally covering 44 countries, Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) has already been issued patents in the U.S. and Australia for the delivery of all non-psychoactive cannabinoids, immediately adding value and validation to the underlying science. Lexaria’s technology is a novel drug delivery platform believed to be applicable across a wide range of different drug types and vitamins, as well as cannabinoids. Lexaria’s lipophilic enhancement technology has been proven to increase both absorption and bioavailability of payload molecules, and the applications and implications are immense.

To clearly communicate this opportunity, Lexaria will host a web-meeting on November 1, 2017, at 4:15 p.m. ET. Lexaria will deliver all the latest news, and, as stated in its newsletter, the company is “expecting to have a LOT to talk about – don’t miss this!” The meeting is open to everyone, but pre-registration is required.

REGISTER here for this important event: https://events.genndi.com/register/169105139238467429/ce8311a9b6

The newsletter also emphasized the fact that Lexaria’s “technology is a delivery platform believed to be applicable to many different types of drugs, vitamins and other substances. It is the applicability of our tech in delivering a substance more efficiently that provides its most substantive value…” To expedite its value proposition, Lexaria has already instructed its attorneys to accelerate examinations of its multiple patent applications wherever possible.

Keeping with strategy, Lexaria is working on several parallel paths toward development of new products and new applications for its technology and seeking new technologies that complement its lipophilic delivery platform. Broad ranging applications will further feed Lexaria’s low-cost, high-margin license and royalty business model of revenue generation. The company’s first licensee is gaining considerable market traction utilizing and paying for its technology, and, with multiple royalty agreements already in the works, Lexaria should easily continue to expand its licensing network. Lexaria has no debt and maintains a healthy cash balance. The company believes it has sufficient cash to follow through with all of the expected R&D and product development, as well as to fund general corporate needs through to the end of 2018.

Lexaria’s novel lipophilic enhancement technology has implications across a wide swath of consumer and pharmaceutical delivery protocols. The global impact of Lexaria’s patented delivery system has barely begun, and it could quickly reverberate to the bottom line.

For more information, visit the company’s website at www.LexariaEnergy.com

Let us hear your thoughts: Lexaria Bioscience Corp. Message Board

• Mobile app market surging
• SWRM targets game development, mobile apps, business apps and e-commerce websites
• Proprietary processes and accretive acquisitions provide competitive advantages

Sometime during the summer of 2018, the mobile app ecosystem, one of the largest nascent industries on the planet, will turn 10 years old. This juvenile ecosystem already encapsulates millions of app developers and billions of smartphone owners who use mobile apps daily. Approximately 197 billion mobile apps are expected to be downloaded this year, and total app downloads are projected to surge to 352 billion by 2021 (http://dtn.fm/EDzb5). From Snapchat to Pokémon Go, top mobile apps are proving to be great productivity and communication tools, in addition to just fun novelties.

However, it’s easy to get overlooked and lost in the vast app ecosystem. Breaking into mainstream business applications and gaining widespread acceptance is extremely difficult, and small developers have been virtually shut out of the $100+ billion global games market by large global game companies, leaving potentially lucrative game apps without commercialization.

Business incubator and accelerator, AppSwarm, Inc. (OTC: SWRM) addresses these critical flaws by providing application developers and entrepreneurs with multiple avenues of monetization. AppSwarm aggressively seeks out application developers who’ve created potentially lucrative apps but can’t effectively get their products to market. When AppSwarm uncovers an application that has money making potential, it connects with the creator and offers multiple strategies of engagement through a stock purchase agreement, a royalty agreement, a joint venture, a partnership or even an outright purchase.

With agreements already in place with all of the major app stores, AppSwarm has the financial resources, business expertise and marketing muscle to launch new mobile applications quickly and effectively. AppSwarm assists and supports application developers during all stages of development by providing concept completion, market analysis, business and financial management and direct sales and marketing in order to maximize monetary impact.

AppSwarm believes it gains competitive advantages in the explosive app ecosystem market through its confidential and proprietary screening process called “The Swarm.” This highly selective screening process involves multiple layers and allows AppSwarm to intensely and accurately scrutinize the benefits and potential of each app idea received before rapidly moving to market.

Over the last year, AppSwarm has announced multiple gaming app acquisitions, partnerships and product launches, as well as acquiring ecommerce websites and announcing plans to develop a full suite of business applications for the small business market. As the company continues to execute its mobile applications strategy and complete synergistic acquisitions within the software development industry, AppSwarm could provide investors interesting opportunities in an explosive ecosystem.

For more information, visit the company’s website at www.App-Swarm.com

Let us hear your thoughts: AppSwarm, Inc. Message Board

• Mobile gaming industry projected to exceed $50 billion within three years
• Tapinator has proven track record with over 300 games and 400+ million player downloads
• Innovation driven, prepping for new wave of lucrative VR and AR games

To the casual observer it may seem frivolous, but mobile gaming is actually a mammoth business. In its very first year, Pokémon Go racked up a mind boggling $950 million in revenue and 500 million downloads (http://dtn.fm/lUt1F), and, with just 19 percent equity, Nintendo earned over $180 million on the game. Candy Crush generated $1.5 billion in revenues last year and earned upwards of $230 million (http://dtn.fm/g29Cf). These eye-popping numbers are serious business.

Newzoo, which provides market intelligence on global games and mobile markets, forecasts that the global games business will grow to $108.9 billion this year, with mobile devices generating the lion’s share of the revenue. Newzoo called mobile the “most lucrative segment” of the gaming industry and predicts 19% year-over-year growth, with mobile gaming representing over half of the total games market by 2020 (http://dtn.fm/wBd1R).

Success in this burgeoning industry is no game. Success requires extensive experience and broad ranging expertise. Tapinator, Inc. (OTCQB: TAPM), with its team of experienced developers, strategists and product specialists, has developed a significant portfolio of mobile gaming titles generating millions of player downloads and repeatedly demonstrated expertise in building scalable, quality gaming products across multiple categories.

Led by visionary CEO Ilya Nikolayev, the Tapinator team has been working together since 2007 building mobile games and applications. With a background in banking and technology, Nikolayev created one of the first successful Facebook applications, which was sold to Intelius, generating substantial returns for all of his investors. Nikolayev is recognized as an industry expert and has been featured on Fox Business, Bloomberg and TheStreet. With his guidance, the Tapinator team has developed and published over 300 mobile gaming titles that have collectively achieved over 400 million player downloads. Tapinator has been recognized in respected publications such as Forbes, Fortune, Venture Beat and The Huffington Post as a “mobile gaming company that has found a balance between profitability and creativity.”

Tapinator maximizes success of its mobile games by using its proprietary set of development and marketing processes based on gaming category, estimated player retention and projected player profitability. The company is constantly testing new technologies and is pioneering forays into virtual (VR) and augmented (AR) reality. Tapinator is prepared to capitalize on these markets, which are projected to exceed $150 billion by 2020.

Mobile gaming is not a game, but rather a lucrative technology- and analytics-driven business. Tapinator, targeting 30+ percent annual growth over the next two years, is proving to be among the innovators and leaders in this industry.

For more information, visit the company’s website at www.Tapinator.com

Let us hear your thoughts: Tapinator, Inc. Message Board

• Biosynthesis technology making strong advances
• Two promising pipeline candidates
• Inclusion in the CSE25 Index

InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) continues down the fast track with its proprietary technology for the microbial biosynthesis of cannabinoids (http://dtn.fm/OBaw0). The company recently announced it has enabled the production of all four “gateway” cannabinoids using genetically engineered microorganisms. From these gateway substrates, production of all 90+ cannabinoids is possible via biosynthesis. InMed’s breakthrough stands to make the production of cannabis derivatives, including THC, CBD and trace cannabinoids, a much more commercially feasible proposition. The Company currently has two lead drug candidates that employ combinations of cannabinoids as the active ingredients. Moreover, as if to put a seal on its step forward, InMed is now included in the CSE25 Index, since it is now one of the twenty-five largest companies in the CSE Composite Index.

To date, over 90+ different cannabinoids have been isolated from the Cannabis sativa plant, the two best known being delta-9-tetrahydrocannabinol (THC), which is responsible for the ‘high’ derived from marijuana, and cannabidiol (CBD). Research into their pharmacological properties has shown that cannabinoids are not all created equally, however: some matter more than others, from a manufacturing process point-of-view. Four key gateway cannabinoids hold the door through which all others must pass:  CBGA, CBNA, CBGV, and CBGVA.  Following the most prevalent synthesis pathway in the plant, CBGA is formed from precursors; downstream enzymes then determine if CBGA diversifies to become tetrahydrocannabinolic acid (THCA), cannabidiolic acid (CBDA), cannabichromene acid (CBCA), or cannabigerol (CBG). Then, further reactions by synthases give rise to a multitude of the most common cannabinoids that so richly endow the plant, including THC and CBD.

InMed’s progress brings scale-up and commercialization of its disruptive biosynthesis process closer to fruition. Traditionally, sourcing cannabinoids has been accomplished by growing, harvesting, processing and purifying (via extraction) the cannabis plant. The extraction process can be expensive, and can result in unwanted by-products and impurities. Biosynthesis mimics the cannabinoid-creation process found in plants by utilizing a microbial host, resulting in pure, individual cannabinoids that will be devoid of the by-products and impurities seen with extraction. The InMed approach is to introduce cannabinoid DNA into E. coli bacteria that results in a biofermentation process, enabling a laboratory-based process under tightly controlled conditions. The process can be tailored to produce any of the 90+ “downstream” cannabinoids found naturally in the cannabis plant. InMed’s biosynthesis program will provide an alternative to the agricultural approach in a low cost and high quality process.  Currently, the Company is actively employing this production chassis to biosynthesize compounds for its pharmaceutical research programs. The possibilities of future growth opportunities are expanded significantly as InMed’s proprietary process may serve as foundation to supply cannabinoids to the pharmaceutical, nutraceutical, medical marijuana and even recreational sectors. What is the potential size of this market? GreenWave Advisors has stated the market for a single cannabinoid, CBD, could grow to $3 billion by 2021 in the US. alone.

Further signaling its rising fortune, InMed has announced (http://dtn.fm/bl2Jz) it is now part of the CSE25 Index, qualifying for the index as one of the twenty-five largest companies by market capitalization on the Canadian Stock Exchange (CSE).

InMed currently has two lead candidates in its drug pipeline. The first, INM-750, is for the treatment of a rare genetic skin disorder, called epidermolysis bullosa (EB), affecting roughly one out of every 20,000 births in the United States. The condition, which currently has no approved treatment or cure, has been called “The Worst Disease You’ve Never Heard Of” by the Dystrophic Epidermolysis Bullosa Research Association of America. INM-750 works two ways. First, it addresses the primary hallmarks of the disease: wound-healing, pain, inflammation, itch, and infection. Second, this compound may have the potential to reverse the course of the disease itself in some patients by upregulating compensatory keratins in the skin to replace defective ones.

The second candidate is INM-085 for the treatment of glaucoma, a leading cause of blindness, according to the Glaucoma Research Foundation. The drug reduces the elevated intra-ocular pressure that is often associated with glaucoma. It is targeting a large market. The National Institutes of Health estimates that more than 3 million Americans currently have glaucoma.

For more information, visit the company’s website at www.InMedPharma.com

Let us hear your thoughts: InMed Pharmaceuticals, Inc. Message Board